NASDAQ:EPZM
Delisted
Epizyme Stock News
$1.47
+0 (+0%)
At Close: Nov 10, 2022
Epizyme, Inc. (EPZM) CEO Robert Bazemore on Q3 2020 Results - Earnings Call Transcript
02:46pm, Friday, 06'th Nov 2020
Epizyme, Inc. (EPZM) CEO Robert Bazemore on Q3 2020 Results - Earnings Call Transcript
Recap: Epizyme Q3 Earnings
07:53am, Friday, 06'th Nov 2020
Shares of Epizyme (NASDAQ:EPZM) remained unaffected after the company reported Q3 results.
Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives
06:05am, Friday, 06'th Nov 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that th
Epizyme Announces Date of Third Quarter 2020 Financial Results
06:30am, Friday, 30'th Oct 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that ma
Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma
12:00am, Wednesday, 07'th Oct 2020
Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma
Is Epizyme (NASDAQ:EPZM) A Risky Investment?
05:05pm, Tuesday, 18'th Aug 2020
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates
03:29pm, Wednesday, 05'th Aug 2020
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
Epizyme Inc (EPZM) Q2 2020 Earnings Call Transcript
09:00pm, Tuesday, 04'th Aug 2020
On the call with me is Rob Bazemore, CEO; Matt Ros, Chief Strategy and Business Officer; and Paolo Tombesi, Chief Financial Officer. Dr. Shefali Agarwal, Chief Medical Officer will join us for the Q&
Epizyme (EPZM) Reports Q2 Loss, Misses Revenue Estimates
11:45am, Tuesday, 04'th Aug 2020
Epizyme (EPZM) delivered earnings and revenue surprises of -3.57% and -47.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Epizyme Q2 Earnings
11:18am, Tuesday, 04'th Aug 2020
Shares of Epizyme (NASDAQ:EPZM) were unchanged after the company reported Q2 results.Quarterly Results Earnings per share decreased 9.43% over the past year to ($0.58), which beat the estimate of ($0.
Epizyme Reports Business Progress and Second Quarter 2020 Financial Results
10:30am, Tuesday, 04'th Aug 2020
Epizyme Reports Business Progress and Second Quarter 2020 Financial Results
Epizyme Reports Business Progress and Second Quarter 2020 Financial Results
12:00am, Tuesday, 04'th Aug 2020
Epizyme Reports Business Progress and Second Quarter 2020 Financial Results
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conferenc
Were Hedge Funds Right About Epizyme Inc (EPZM)?
10:31pm, Thursday, 16'th Jul 2020
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that sm
